RBMS3

Across TCGA pan-cancer cohorts, RBMS3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBMS3 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher RBMS3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMS3 expression acts as an unfavorable survival marker.

LGG, UCEC, and SKCM are the cancer types where RBMS3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.177	0.739	<.001	12	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	5	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
BRCA	OS	Median	All	0.763	0.924	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBMS3–LGG (DFS)

Open the LGG breakdown →